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Excretion and Tissue Disposition of
Dichioroacetonitrile in Rats and Mice
by Mark R. Roby,* Sigrid Carle,* Michael A. Pereira,t
and Dean E. Carter**
The excretion and tissue distribution of [1-14C]dichloroacetonitrile and [2-'4C]dichloroacetonitrile were
studied in male Fischer 344 rats and male B6C3F1 mice. Three dose levels ofdichloroacetonitrile (DCAN)
(0.2, 2, or 15 mg/kg) were administered to rats and two dose levels ofDCAN (2 or 15 mg/kg) to mice. Daily
excreta including exhaled volatiles and radiolabeled carbon dioxide (14CO2) were analyzed for radiolabeled
carbon (14C) until > 70% of the radioactivity was excreted. At that time the animals were sacrificed and
tissues were collected. Tissues and excreta were analyzed for 14C by combustion and liquid scintillation
counting. Rats administered [1-14C]DCAN excreted 62 to 73% ofthe 14C in 6 days, with 42 to 45% in urine,
14 to 20% in feces, and 3 to 8% as CO2. Rats administered [2-14C]DCAN excreted 82 to 86% of the '4C in
48 hr, with 35 to 40% in urine, 33 to 34% as CO2, and 10 to 13% in feces. Mice administered [1-14C]DCAN
excreted 83 to 85% ofthe '4C in 24 hr, with 64 to 70% in urine, 9 to 13% in feces, and 5 to 6% as CO2. Mice
administered [2-14C]DCAN excreted 84 to 88% ofthe '4C in 24 hr with 42 to 43% in urine, 8 to 11% in feces,
and 31 to 37% as CO2. Liver tissues retained the most 14C in all studies except the study of [1-14C]DCAN
in rats, where blood contained the most 14C.
These results indicate that DCAN was absorbed rapidly after oral administration in water. The differ-
ences in the route ofexcretion of[1-14C]DCAN compared to [2-14C]DCAN indicated that the molecule was
being cleaved in the body and metabolized by different mechanisms.
Introduction
The chlorination ofdrinking water results in the for-
mation of by-products including trihalomethanes and
halogenated acetonitriles. Dihaloacetonitriles havebeen
found in chlorinated drinking water at a concentration
of 0.3 to 8.1 ppb (1). Haloacetonitriles bind to poly-
adenylic acid without enzymatic activation. They also
induce DNAstrandbreakage incultured human CCRF-
CEM cells (2). Several haloacetonitriles induced tumors
when applied to the skin of SENCAR mice (3). There-
fore, haloacetonitriles possess the potential for carcin-
ogenic activity.
This paper examines the excretion and organ distri-
bution ofdichloroacetonitrile (DCAN) after oral admin-
istration toratsand mice as apart ofthetoxicity studies
forthiscompound. We haveexaminedthese parameters
with DCAN radiolabeled on each ofthe two carbon at-
oms. Differences indisposition ofthese tworadiolabeled
compounds determine if the molecule is degraded into
one-carbon fragments.
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Methods
The [1-14C]DCAN (specific activity 5.0 mCi/mmole)
and [2-14C]DCAN (specific activity 4.04 mCi/mmole)
were purchased from New England Nuclear (Boston,
MA). These radiolabeled compounds were purified by
distillation in amolecular still (Ace Glass Co., Vineland,
NJ) before the dosing solutions were prepared. Purity
ofthe compounds was > 98% as measured by reverse-
phase, high-performance liquid chromatography
(HPLC) when the dosing solutions were prepared, but
slow degradation ofthe compound occurred after prep-
aration. HPLC conditions included a solvent of 1:1
(v/v)acetonitrile:water on a 10 PI C18 Alltech (Deerfield,
IL) column using ultraviolet detection at 195 nm. Un-
labeled DCAN purchased from Pfaltz and Bauer (Wa-
terbury, CT) was determined to be > 98% pure by gas
liquid chromatography (GLC) using a 30 m OV 1701
capillary column and a flame ionization detector.
Male Fischer 344 rats weighing 170-250 g and male
B6C3F1 mice weighing 18-25 g at the time of admin-
istration were purchased from Harlan Sprague-Dawley
(Walkersville, MD). Animals were housed individually
in glass metabolism cages (Vanguard International,
Neptune, NJ) designed to collect all exereta separately.
Exhaled carbon dioxide (CO2) was collected in a 100 mL
volume of solution of 2:1 (v/v)Carbosorb (Packard In-ROBY ETAL.
struments, Downers Grove, IL): ethylene glycol, and
unchanged DCAN collected in 25 mL of2-methoxyethyl
ether (Aldrich Chemicals, Milwaukee, WI). Food
(Wayne Lab Blox, Chicago, IL) and water were pro-
vided ad libitum, and the animals were maintained on
a 12-hr light-dark cycle.
Three dose levels (15.0, 2.0, or 0.20 mg/kg) were or-
ally administered to rats (n = 3), and two dose levels
(15.0 or 2.0 mg/kg) were orally administered to mice (n
= 3). Dosing solutions for rats were prepared in water
such that each animal received 40 ,uCi/kg for the 15 and
2 mg/kg doses in a 0.3 to 0.5 mL volume. The 0.2 mg/
kg dose in rats was limited to 9 piCi/kg because of the
specific activity of the radiolabel. Dosing solutions for
mice were prepared in water such that each animal re-
ceived 10 ,uCi at the 15 mg/kg dose. The 2 mg/kg dose
was limited to 2 ,iCi per animal, and the 0.2 mg/kgdose
could not be prepared because of specific activity limi-
tations. Urine, feces, and expired air were collected
daily and counted for radioactivity; the percentage of
dose excreted per day was calculated except for those
mice from which a 6.5-hr sample was also taken. The
experiments were continued until > 70% of the radio-
labeled carbon (14C) was excreted, at which point the
animals were sacrificed. This condition was met at 6
days for [1-14C]DCAN, at 2 days for [2-14C]DCAN in
rats, and at 24 hr in mice. Urine samples (combined
with the cage wash) (0.5-1 mL), Carbosorb/ethylene
glycol, and 2-methoxyethyl ether solutions were
counted after addition to Beta Phase scintillation fluid
(Westchem Products, San Diego, CA). A Beckman
LS2800 (Beckman Instruments, Fullerton, CA) was
used forliquid scintillation counting (LSC). Feces (com-
bined with intestinal contents) were homogenized in 5
mL/g of1N KOH in water. Samples ofthe homogenates
were combusted to 14CO2 in a Packard Tri Carb (Pack-
ard Instrument Co., Downers Grove, IL) sample oxi-
dizer and quantified for radioactivity by LSC. Animals
were sacrificed by CO2 inhalation, and blood samples
were obtained by cardiac puncture. At sacrifice, brain,
lung, liver, kidney, small and large intestine, stomach,
testes, and samples of adipose tissue (testicular), skin,
and muscle were removed. Organs were weighed, and
0.1 g samples were combusted in the tissue oxidizer as
described above. For nondiscrete tissues in rats (blood,
adipose tissue, skin, and muscle) total tissue weights
were estimated as 9, 7, 16 and 50% of body weight
respectively (4). For mice, the corresponding tissue
weight estimates were 7.6, 9.8, 14.5, and 45%, respec-
tively (5). The percentage ofdose was calculated for all
tissues at each time point.
Statistical comparisons were determined by analysis
of variance and least significant difference tests. Dif-
ferences were considered significant at p < 0.05.
Results
To determine if the dose affected the excretion or
disposition of DCAN, the animals were orally admin-
istered 0.2, 2.0, and 15 mg/kg [14C]DCAN. The highest
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FIGURE 1. Cumulative excretion of [1-'4C] DCAN (as 14C equiva-
lents) after oral administration to rats: (01)15 mg/kg; (0)2 mg/kg;
(A)0.20 mg/kg as aqueous solutions. Values are expressed as per-
centage of administered dose, x + SD, n = 3.
dosage level represented 5-10% ofthe oral LD50 value
of2 mmole/kgdetermined for rats (data not presented).
DCAN radiolabeled on each carbon atom was admin-
istered to measure differences in the excretion or dis-
position of the individual carbon atoms.
[1-14C]DCAN in Rats
Between 40 and 54% of the [1-14C]DCAN dose was
excreted within 24 hr at all dose levels (Fig. 1). After
48 hr, the rate ofexcretion decreased slowly to a range
of 2 to 4% per day. By 6 days, 62 to 73% of the dose
had been eliminated. At this time, most ofthe excreted
radioactivity was recovered in the urine (42 to 45% of
the dose). Lesser amounts were found in feces (14 to
20%) and in exhaled air. The exhaled air contained 3 to
8% of the dose as carbon dioxide with less than 1%
appearing in the organic trap (Table 1). Analysis of var-
iance comparing the percentage ofadministered 14C ex-
creted versus the dose level showed that the fecal elim-
ination and carbon dioxide exhalation were significantly
greater at the 15 mg/kg dose than at the lower doses.
The carbon dioxide exhalation at 2 mg/kg was also
greater than the 0.2 mg/kg dose, and the urinary ex-
cretion was lower at the 2 mg/kg dose than the other
doses.
After 6 days, the tissues retained 19.3% ofthe dose.
Table 1. Cumulative expiration of [1-14C]DCAN (as 14C
equivalents) 48 hr after oral administration to rats.a
[1-14C]DCAN, % of dose
15 mg/kg 2.0 mg/kg 0.20 mg/kg
CO2 8.1 ± 2.5 5.2 ± 0.6 3.2 ± 0.2
Organic 0.8 ± 0.2 0.4 ± 0.1 N.S.b
aValues are expressed as percentage of administered dose. x ±
SD, n = 3.
bN.S. = not sampled.
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Table 2. Tissue levels of (1-14C)DCAN (as 14C equivalents) 6 days
after oral administration to rats.a
Tissue levels of [1-14C]DCAN, % ofdose
Tissue
Blood
Liver
Muscle
Skin
Kidney
Adipose tissue
Gastrointestinal
Brain
Lung
Testes
Total recovery
15 mg/kg
7.22 ± 1.44
1.88 ± 0.34
3.88 ± 0.47
3.32 ± 0.37
0.35 ± 0.05
0.48 ± 0.08
0.97 ± 0.24
0.06 ± 0.01
0.14 ± 0.02
0.14 ± 0.03
90.44 ± 1.52
2.0 mg/kg
7.89 ± 1.01
2.60 ± 0.35
6.88 ± 0.76
6.25 ± 0.92
0.44 ± 0.04
0.57 ± 0.06
1.60 ± 0.17
0.06 ± 0.01
0.20 ± 0.06
0.27 ± 0.05
90.42 ± 1.01
0.20 mg/kg
4.12 ± 1.36
2.13 ± 0.33
7.88 ± 1.68
6.13 ± 0.24
0.37 ± 0.01
0.63 ± 0.08
1.91 ± 0.28
0.05 ± 0.01
0.17 ± 0.04
0.23 ± 0.06
89.13 ± 2.13
aValues are expressed as percentage of administered dose, x +
SD, n = 3. Recovery include radioactivity from tissues and all ex-
creta.
Blood retained the highest amount (4 to 8%) followed
by muscle (4 to 8%), skin (3 to 6%), and liver (2 to 3%)
(Table 2). Total recovery ofadministered 14C in tissues,
body fluids, urine, and feces found in this study ranged
from 89.1 to 90.4%.
[2-14C]DCAN in Rats
At the three dose levels of[2-14C]DCAN, between 71
and 78% ofthe dose was excreted within 24 hr (Fig. 2).
This percentage had increased to 82 to 86% ofthe dose
at48hrwhentheexperimentwasterminated. Theurine
contained 35 to 40% ofthe 14C after 48 hr. The expired
air contained 33 to 34% of the dose with 0.28 to 0.37%
ofthe dose in the organic trap (data not shown) and the
remainder as carbon dioxide. Lesser amounts were
found in feces (10 to 13%). Analysis of variance com-
paringthepercentage ofadministered 14C excretedver-
sus the dose level showed no significant differences in
excretion among these doses.
After 2 days, the tissues retained 12 to 17% of the
dose. Liver retained the highest amount (5.2 to 5.7%)
followed by muscle (3 to 5%), blood (2 to 5%) and skin
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Table 3. Tissue levels of(2-`QC) DCAN (as 14C equivalents)
2 days after oral administration to rats.a
Tissue levels of [2-14C]DCAN, % of dose
Tissue 15 mg/kg 2.0 mg/kg 0.20 mg/kg
Blood 4.57 ± 1.99 2.02 ± 0.60 2.47 ± 0.19
Liver 5.67 ± 0.54 5.23 ± 0.32 5.70 ± 0.45
Muscle 3.37 ± 1.07 2.74 ± 0.96 4.78 ± 0.51
Skin 1.62 ± 0.24 0.94 ± 0.02 1.61 ± 0.06
Kidney 0.47 ± 0.04 0.37 ± 0.01 0.47 ± 0.03
Adipose tissue 0.31 ± 0.02 0.35 ± 0.12 0.93 ± 0.27
Gastrointestinal 0.71 ± 0.13 0.59 ± 0.04 0.76 ± 0.09
Brain 0.08 ± 0.02 0.05 ± 0.01 0.08 + 0.00
Lung 0.12 ± 0.01 0.07 ± 0.01 0.10 + 0.02
Testes 0.10 ± 0.01 0.07 ± 0.01 0.12 ± 0.01
Total recoverv 100.54 ± 6.16 94.44 ± 5.89 103.47 ± 6.08
aValues are expressed as percentage of administered dose, x +
SD, n = 3. Recovery includes radioactivity from tissues and all ex-
creta.
(1 to 2%) (Table 3). Total recovery ofadministered 14C
intissue, bodyfluids, urine, andfecesfoundinthisstudy
ranged from 94 to 103%.
[1-14C]DCAN in Mice
The excretion of [1-14C]DCAN was substantially
more rapid in B6C3F1 mice than in F-344 rats. At the
15 and 2.0 mg/kg dose levels tested, 84.6 and 82.5%,
respectively, ofthe dose were eliminated by 24 hr. The
urine contained 69.7% ofthe 15 mg/kg dose and 63.5%
of the 2 mg/kg dose, and the feces contained 9.1 and
13.1%, respectively (Fig. 3). Only 0.43% ofthe 15 mg/
kg dose and 0.31% ofthe 2 mg/kg dose were expired as
organics, whereas at these doses, 5.3 to 5.6% was ex-
piredas CO2. Statisticaltestscomparingthepercentage
of administered 14C excreted versus the dose level
showed anincreasedfecalelimination atthelowerdose.
After 24 hr, the tissues contained 11 to 12% of the
dose. The liver had the highest amount ofradioactivity
(3.5 to 4.2% of the dose) followed by almost equal
amounts in muscle and skin (1.6 to 2.1%) and in blood
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Figure 2. Cumulative excretion of (2-14C) DCAN (as 14C equiva-
lents) after oral dosing to rats. Administered in 15, 2, and 0.21
mg/kg aqueous solutions. Values are expressed as percentage of
administered dose, 2 + SD, n = 3.
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FIGURE 3. Cumulative excretion of (1-14C) DCAN (as 14C equiva-
lents) after oral administration to mice. Administered in 15 and 2
mg/kg aqueous solutions. Values are expressed as percentage of
administered dose, 2 _ SD, n = 3.
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Table 4. Tissue levels of (1-14C) DCAN (as '4C equivalents) 1 day
after oral administration to mice.'
Tissue levels of [1-14C]DCAN, % of dose
Tissue 15 mg/kg 2.0 mg/kg
Blood 1.11 ± 0.28 0.95 ± 0.19
Liver 3.48 ± 0.43 4.25 ± 0.35
Muscle 2.11 ± 0.53 1.56 ± 0.11
Skin 2.02 ± 0.55 1.69 ± 0.21
Kidney 0.38 ± 0.10 0.46 ± 0.02
Fat 1.22 ± 0.55 0.89 ± 0.23
Gastrointestinal 1.46 ± 0.27 1.59 ± 0.27
Brain 0.04 ± 0.02 0.03 ± 0.01
Lungs 0.08 ± 0.04 0.07 ± 0.01
Testes 0.05 ± 0.03 0.04 ± 0.02
Total recovery 97.55 ± 1.12 95.49 ± 3.12
aValues are expressed as percentage of administered dose, 2 +
SD, n = 3. Recovery include radioactivity from tissues and all ex-
creta.
and fat (0.9 to 1.2%) (Table 4). Total recovery was 97.6
and 95.2% for the 15 and 2 mg/kg doses, respectively.
[2-14C]DCAN in Mice
The [2-14C]DCAN was also excreted rapidly with
83.8% of the 15 mg/kg dose and 88.0% of the 2 mg/kg
dose eliminated in24hr. Theurine contained thelargest
amount of radioactivity, with 42 to 43% of the dose at
the two doses tested (Fig. 4). The CO2 found in expired
air contained 31 to 37% ofthe administered radioactiv-
ity. Lesser amounts were found in feces: 11% of the
dose was recovered at the 15 mg/kg dose and 7.5% at
the 2 mg/kg dose. Small amounts of radioactivity (0.2
to 0.4%) were found in the organic trap in expired air.
Statistical tests comparing the percentage of adminis-
tered 14C eliminated versus the dose level showed
greater fecal elimination at the high dose and greater
carbon dioxide exhalation at the lower dose.
After 24 hr, the tissues contained about 9% of the
dose. Thelivercontained mostoftheradioactivity (-5%
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FIGURE 4. Cumulative excretion of (2-14C) DCAN (as 14C equiva-
lents) after oral dosing to mice. Administered in 15 and 2 mg/kg
aqueous solutions. Values are expressed as percentage of admin-
istered dose, x + SD, n = 3.
Table 5. Tissue levels of(2-`4C) DCAN (as 14C equivalents) 1 day
after oral administration to mice.a
Tissue levels of [2-'4C] DCAN, % of dose
Tissue 15 mg/kg 2.0 mg/kg
Blood 0.29 ± 0.07 0.27 ± 0.08
Liver 5.12 ± 1.14 5.37 ± 0.43
Muscle 1.03 ± 0.06 0.79 ± 0.21
Skin 0.45 ± 0.04 0.52 ± 0.09
Kidney 0.56 ± 0.15 0.50 ± 0.04
Fat 0.62 ± 0.05 0.38 ± 0.11
Gastrointestinal 0.65 ± 0.12 0.80 ± 0.26
Brain 0.04 ± 0.01 0.03 ± 0.01
Lungs 0.04 ± 0.01 0.03 ± 0.01
Testes 0.02 ± 0.00 0.05 ± 0.05
Total recovery 92.94 ± 3.55 96.55 ± 2.15
aValues are expressed as percentage of administered dose, x +
SD, n = 3. Recovery includes radioactivity from tissues and all ex-
creta.
ofthe dose) with smaller amounts found in muscle (0.8
to 1.0%), kidney (0.5 to 0.6%), and skin (0.45 to 0.52%)
(Table 5). All other tissues contained less than 0.5% of
the dose. Total recovery was 92.9% for the 15 mg/kg
dose and 96.6% for the 2 mg/kg dose.
Discussion
The use of DCAN radiolabeled at the two different
carbon atoms allowed us to determine if the molecule
was degraded into one-carbon fragments. Substantial
differences in the rate and route of excretion of [1-
14C]DCAN, labeled on the cyanide (CN) group com-
pared to [2-14C]DCAN, labeled on the dichloromethyl
group, were found in rats. In mice, the major differ-
ences between these labeled compounds were in the
route of excretion.
After oral administration, DCAN was rapidly ab-
sorbed in rats and mice. If all the radioactivity that
appeared in the feces was unabsorbed material, then
absorption would be estimated at approximately 90% of
the dose. Since bilary excretion may account for some
DCAN orits metabolites found infeces, absorption may
begreaterthan90%. Statistically significant differences
in fecal elimination were found whenthe different doses
of [1-14C]DCAN were compared, but they were not ob-
served for [2-14C]DCAN. These fecal elimination dif-
ferences cannot reflect absorption limitations, as both
labeled compounds would act in a similar manner and
must reflect differences in metabolism or elimination.
Significant differences in the amount of 14CO2 for-
mation were found for [1-14C]DCAN and [2-14C]DCAN
in rats and mice. For [1-14C]DCAN, about 5% of the
radioactivity was eliminated as 14CO2, whereas for [2-
14C]DCAN, about 35% was eliminated in both rats and
mice. The 14CO2 exhalation was essentially complete in
24hreventhoughurinaryandfecalexcretionrateswere
quite different between rats and mice.
These results are consistent with the postulated me-
tabolism of DCAN. Pereira and workers (6) proposed
that DCAN would be metabolized to cyanide and phos-
gene or formyl chloride. The active intermediate could
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also degrade to form chloride ion and formyl cya-
nide[Eq. (1)]. The two pathways will lead to the same
degradation products-chlorine, formic acid, CO2, and
CN. These experiments cannotdistinguishthedifferent
pathways but can determine the fate of each carbon
atom. If the metabolism of DCAN was rapid, [1-
14C]DCAN would be expected to be excreted like cya-
nide ion and [2-14C]DCAN like a molecule producing
phosgene or formyl chloride.
CHCIFN - C(OH)CI2CN
/ (1)
CICOCI + HCN CICOCN + HCI
The disposition and excretion of [1-14C]DCAN was
similar to results from studies on the disposition ofcy-
anide. Cyanide administered intravenously to rats
formed about 8% 14CO2 in 7 days (7). The major route
ofexcretion after cyanide administration was the urine;
in 24 hr, 45% of the radiolabeled dose was excreted in
theurineandthispercentageincreasedto68%at7days.
Our studies showed a 24-hr urinary excretion of 28 to
31% in rats and 38 to 44% of the radiolabeled dose in
mice. A total of 42 to 45% of the dose appeared in the
urine by 6 days in rats. The feces contained 14% ofthe
dose by 7 days in the cyanide studies compared to 14
to20% in 6days in ourstudies. Majortissues containing
radioactivity after cyanide dosing were blood (values
notgiven), gastrointestinal tract (4.1%), muscle (1.8%),
and liver (0.6%). Blood, muscle, and liver had the high-
est radioactivity levels after administration of [1-
14C]DCAN. The gastrointestinal tract levels were only
1 to 2% for DCAN and were less than those found for
cyanide. Cyanide appeared to concentrate in the gas-
trointestinal tract after being trapped in the stomach.
After administration of[14C]cyanide, radioactivity was
found in several endogenous compounds including cho-
line, methionine, allantoin, and fatty acids (8). The cy-
anide carbon probably entered the one-carbon pool
through formation ofthe formate ion, and a slow elim-
inationofradioactivity occurred afterthefirstfewdays.
These findings are consistent with the slow elimination
of[1-14C]DCAN inrats. Anotherindicationthatcyanide
was formed from DCAN wastheincreasedurinarythio-
cyanite levels found by Pereira and coworkers (6) after
administering DCAN to rats.
The metabolism of[2-14C]DCAN would result in the
formation ofradiolabeled phosgene in a manner analo-
gous to chloroform. Chloroform is metabolized to phos-
gene, and this reactive intermediate reacts with pro-
teins and amino acids or is further degraded to CO2 (9,
10). The recoveries in exereta of chloroform and [2-
14C]DCAN are difficult to compare since the predomi-
nant route of chloroform elimination is exhalation of
unchanged compound. The total amount of 14CO2 col-
lected after oral [14C]chloroform administration of 60
mg/kg to rats was 66%, and the amount of'4C excreted
in the urine and feces was 7.6% (11). Approximately
equal amounts of radioactivity were found in CO2 and
inurineafteroraladministrationof[2-14C]DCANinrats
and mice. These differences between chloroform and
DCAN may be caused by the presence of other meta-
bolic routes for DCAN. Protein binding of 14C to liver
was found both after [14C]chloroform administration (9)
and after [14C]DCAN administration (2).
The differences in excretion rates between rats and
mice may result from ahigher rate ofmetabolism in the
mouse for compounds such as chloroform (11) or from
different routes of metabolism. Urinary metabolites
must be identified before these possibilities can be dis-
tinguished.
Some dose-related differences in excretion were
noted in these studies. These differences were partic-
ularly notable for the CO2 exhalation in rats adminis-
tered [1-14C]DCAN and forfecal elimination and carbon
dioxide exhalation in mice administered [2-14C]DCAN.
Sincethese differenceswere notseenforDCAN labeled
ontheothercarbonatominthesame species, theeffects
probably did not result from the absorption or metab-
olism ofDCAN. Rather, theyresulted frommetabolism
or excretion ofthe metabolic products and wili require
metabolite identification for interpretation.
Insummary, DCAN wasrapidly absorbed inrats and
mice after oral administration. Differences in the route
ofexcretion of[1-14C]- and [2-14C]DCAN indicated that
themolecule was cleaved inthe bodyandthatthemajor
differences were in the extent of CO2 formation. Mice
excreted both labeled compounds by the same routes
as rats, but the rate ofexcretion was much more rapid.
Distribution after > 70% ofthe radioactivity had been
excreted showed that the liver contained the highest
amount ofthe dose except in the study of[1-14C]DCAN
inrats inwhichthehighestlevelsofthedosewerefound
in the blood.
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